Enovis Corp 2026年季度报告

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 ofRegulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes☑No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerginggrowth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of theExchange Act. Large accelerated filer☑Accelerated filer☐Non-accelerated filer☐ Smaller reporting company☐Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revisedfinancial accounting standards provided pursuant to Section 13(a) of the Exchange Act☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☑ As of May1, 2026, there were 57,562,603 shares of the registrant’s common stock, par value $.001 per share, outstanding. TABLE OF CONTENTS PagePART I - FINANCIAL INFORMATIONItem 1. Financial Statements2Condensed Consolidated Statements of Operations2Condensed Consolidated Statements of Comprehensive Income (Loss)3Condensed Consolidated Balance Sheets4Condensed Consolidated Statements of Equity5Condensed Consolidated Statements of Cash Flows6Notes to Condensed Consolidated Financial Statements7Note 1. General7Note 2. Recently Issued Accounting Pronouncements7Note 3. Acquisitions and Investments8Note 4. Revenue8Note 5. Net Loss Per Share from Continuing Operations10Note 6. Income Taxes10Note 7. Equity11Note 8. Inventories, Net13Note 9. Debt13Note 10. Accrued Liabilities15Note 11. Financial Instruments and Fair Value Measurements15Note 12. Commitments and Contingencies19Note 13. Segment Information19Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations24Item 3. Quantitative and Qualitative Disclosures About Market Risk40Item 4. Controls and Procedures42PART II - OTHER INFORMATIONItem 1. Legal Proceedings43Item 1A. Risk Factors43Item 2. Unregistered Sales of Equity Securities and Use of Proceeds43Item 3. Defaults Upon Senior Securities43Item 4. Mine Safety Disclosures43Item 5. Other Information43Item 6. Exhibits44SIGNATURES45 ENOVIS CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSDollars in thousands, except per share amounts(Unaudited) ENOVIS CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)Dollars in thousands(Unaudited) ENOVIS CORPORATIONCONDENSED CONSOLIDATED BALANCE SHEETSDollars inthousands, except share amounts(Unaudited) ASSETSCURRENT ASSETS:Cash and cash equivalents$33,129$36,389Trade receivables, less allowance for credit losses of $30,219 and $25,609444,206442,786Inventories, net602,543584,379Prepaid expenses49,51742,283Other current assets110,286101,222Total current assets1,239,6811,207,059Property, plant and equipment, net519,721507,063Goodwill711,903718,299Intangible assets, net1,192,4871,236,713Lease asset - right of use74,50072,256Other assets93,96493,347Total assets$3,832,256$3,834,737 ENOVIS CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSDollars inthousands(Unaudited) ENOVIS CORPORATIONNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited) 1. GeneralEnovis Corporation (the “Company” or “Enovis”) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. The Companyconducts its business through two operating segments, Prevention & Recovery (“P&R”) and Reconstructive (“Recon”). The P&R segmentprovides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injuryprevention to rehabilitation after surgery, injury, or from degenerative disease. The Recon segment provides surgical implant solutions,offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgicalproductivity tools. The Condensed Consolidated Financial Statements included in this quarterly report have been prepared by the Company in accordancewith the rules and regulations of the Securities and Exchange Commission (“SEC”) and accounting principles generally accepted in theUnited States of America (“GAAP”) for interim financial statements and reflect, in the opinion of management, all adjustments, whichconsist solely of normal recurring adjustments, necessary to present fairly the Company’s financial position and results of operations as ofand for the periods indicated. The Condensed Consolidated Balance Sheet as of Dec